Fate Therapeutics, Inc. <FATE.O>: Wells Fargo raises target price to $3.5 from $2.5
FATE•Related News
Engine Capital Urges H.B. Fuller’s Board Of Directors To Run A Market Check For The Building Adhesive Solutions Segment And The Entire Company
FUL•
Eton Pharmaceuticals rises on Q2 profit beat
ETON•
Creative Media & Community Trust Q2 loss narrows on higher multifamily occupancy
CMCT•
Asian spot LNG prices rise as Hormuz reopening hopes fade
XLE•
Fate Therapeutics starts potentially registrational Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis
FATE•